Vaccine for Rift Valley Fever

Summary of the technology

Vaccine for Rift Valley Fever
The CSIC, through INIA-CSIC and its Animal Health Research Center, has developed a live attenuated vaccine for Rift Valley Fever, an emerging zoonotic viral disease of great economic impact on animal health that can also affect humans. There is not a treatment or vaccine on the market, so this vaccine can be used to develop safe and effective control strategies, both for animal and human use.
We are looking for companies in the biopharmaceutical sector interested in the development of vaccines, both for the animal health sector and for human medicine.
An offer for Patent Licensing

CSIC - Consejo Superior de Investigaciones Científicas

First attenuated virus based vaccine against Rift Valley Fever

The vaccine can be administered to domestic (cows, sheep, goats, camels) and wild (buffalo) ruminants, as well as humans .
Live attenuated vaccines induce long-lasting and broadly protective immunity after a single dose administration in both animals and humans.
They are called live vaccines because they contain the infecting organism in a live or viable form, but with a greatly reduced (attenuated) virulence. This makes them an excellent basis for developing a successful immunization program in affected countries or for implementing preventive control measures in countries with a higher risk of introducing or spreading the disease.
It´s been characterized a variant of the RVF virus obtained in the laboratory by serial passages in the presence of a mutagenic agent, favipiravir. This variant, called 40F-p8, was highly attenuated in immunodeficient mice extremely sensitive to viral infections, without altering its ability to induce a protective immune response in immunocompetent mice. Furthermore, they have identified a number of specific mutations throughout the viral genome that can be potential virulence determinants.

Main innovations and advantages

  • The main problem of live attenuated virus-based vaccines is associated with the residual virulence of the formulations used
  • This virus variant could be the basis of a new vaccine strain with safety parameters not previously described
  • A pharmaceutical or veterinary composition is provided comprising the VFVR variant
  • It can be administered to domestic (cows, sheep, goats, camels) and wild (buffalo) ruminants, as well as humans.

Intellectual property status

  • Granted Patent
  • Patent application number :-

Related Keywords

  • Pharmaceutical Products / Drugs
  • Agriculture
  • Plant and animal health
  • Animal health
  • vaccine
  • rift valley fever

About CSIC - Consejo Superior de Investigaciones Científicas

The Spanish National Research Council (in Spanish 'Consejo Superior de Investigaciones Científicas (CSIC)') is a government agency for basic and applied scientific research.

It is the largest public research organization in Spain, with presence in all the Autonomous Communities through 126 centers and 145 associated units.

CSIC - Consejo Superior de Investigaciones Científicas

Never miss an update from CSIC - Consejo Superior de Investigaciones Científicas

Create your free account to connect with CSIC - Consejo Superior de Investigaciones Científicas and thousands of other innovative organizations and professionals worldwide

CSIC - Consejo Superior de Investigaciones Científicas

Send a request for information
to CSIC - Consejo Superior de Investigaciones Científicas

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support